Bullish & Foolish
Full OCGN fundamentals All 466 on the Survival Watch

OCGNOCUGEN, INC.

Is Ocugen struggling financially?

Yes, by its own account. Ocugen told the SEC on 8 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$471.4M
Source filing
10-Q 8 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 17months

    If the burn speeds up

    Empty by Nov 2027

  • 25months

    If it eases off

    Empty by Jul 2028

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$100.1M

÷

Cash burned over the last 12 months

$57.1M

What Ocugen told the SEC

…with the anticipated continued spending that will be necessary to continue to research, develop, and commercialize the Company's product candidates, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The condensed consolidated financial statements do not contain any adjustments that…

OCUGEN, INC., Form 10-Q, filed 8 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 14.1% share-count increase The company issued stock. Each share now owns 12.3% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 40% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt